MannKind reported $108.52M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Adma Biologics USD 95.28M 19.52M Sep/2026
BioCryst Pharmaceuticals USD 195.83M 13.02M Sep/2026
Eli Lilly USD 47B 745M Sep/2026
Halozyme Therapeutics USD 476.09M 131.65M Sep/2026
Insmed USD 596.57M 157.83M Sep/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
MacroGenics USD 107.23M 1.58M Sep/2026
MannKind USD 108.52M 34.37M Sep/2026
Merck USD 28.8B 1.07B Sep/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Novavax USD 329.84M 729K Sep/2026
Novo Nordisk DKK 36.54B 188.62B Jun/2026
Pfizer USD 31.73B 920M Sep/2026
Sanofi EUR 29.77B 2.16B Sep/2026
Xencor USD 76.27M 5.6M Sep/2026